Anika Therapeutics Inc (NASDAQ:ANIK) Director Jeffery S. Thompson sold 10,725 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $47.39, for a total value of $508,257.75. Following the sale, the director now owns 15,845 shares in the company, valued at approximately $750,894.55. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Anika Therapeutics Inc (NASDAQ:ANIK) traded down 0.85% during mid-day trading on Tuesday, reaching $46.41. The company’s stock had a trading volume of 59,661 shares. The stock’s 50 day moving average is $45.15 and its 200 day moving average is $46.86. Anika Therapeutics Inc has a 12 month low of $41.38 and a 12 month high of $54.96. The company has a market cap of $680.09 million, a price-to-earnings ratio of 22.40 and a beta of 1.85.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by $0.01. The firm had revenue of $23.39 million during the quarter, compared to the consensus estimate of $23.89 million. Anika Therapeutics had a net margin of 33.64% and a return on equity of 17.21%. Anika Therapeutics’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 EPS. Equities research analysts predict that Anika Therapeutics Inc will post $1.99 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/23/anika-therapeutics-inc-anik-director-sells-508257-75-in-stock.html.

A number of institutional investors have recently modified their holdings of the company. Chicago Equity Partners LLC bought a new position in shares of Anika Therapeutics during the third quarter worth about $294,000. BlackRock Fund Advisors boosted its position in shares of Anika Therapeutics by 9.9% in the third quarter. BlackRock Fund Advisors now owns 1,036,596 shares of the biotechnology company’s stock worth $49,601,000 after buying an additional 93,300 shares during the period. New York State Common Retirement Fund boosted its position in shares of Anika Therapeutics by 19.9% in the third quarter. New York State Common Retirement Fund now owns 60,560 shares of the biotechnology company’s stock worth $2,898,000 after buying an additional 10,055 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in shares of Anika Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,180 shares of the biotechnology company’s stock worth $152,000 after buying an additional 50 shares during the period. Finally, Citadel Advisors LLC boosted its position in shares of Anika Therapeutics by 683.3% in the third quarter. Citadel Advisors LLC now owns 20,463 shares of the biotechnology company’s stock worth $980,000 after buying an additional 23,971 shares during the period. Hedge funds and other institutional investors own 76.53% of the company’s stock.

Separately, Zacks Investment Research downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 8th.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

12 Month Chart for NASDAQ:ANIK

Receive News & Ratings for Anika Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.